KAD Clinical Research Proudly Debuts on Global Fatty Liver Day

KAD Clinical Research announced its official launch today, on Global Fatty Liver Day, as a full-service, dedicated clinical research site focused on hepatology and metabolic diseases. The timing underscores the company’s mission to improve medications and therapies for patients living with fatty liver disease and related metabolic conditions, including but not limited to diabetes, obesity and hyperlipidemia.

Although newly established, KAD Clinical Research is built on the expertise of respected leaders in liver and metabolic research, with decades of experience in clinical trials, drug development and regulatory strategy.

Located in St. Louis, Missouri, KAD Clinical Research is strategically embedded within an already high-performing research center, allowing it to focus on therapeutically targeted conditions and treatments. Purpose-built for trial success, KAD Clinical Research offers comprehensive phase I-IV clinical trial execution with expert leadership, rapid start-up, patient recruitment and screening, regulatory compliance, and advanced noninvasive diagnostics. The site partners with sponsors, CROs and referring physicians to meet the evolving needs of patients and accelerate study timelines.

KAD Clinical Research was founded by Kristina Wriston, BSN, RN, CCRC (chief executive officer), Adrian M. Di Bisceglie, MD, FACP, FAASLD (chief medical officer), and Derek Vanover, Esq. (general counsel), and is rooted in deep scientific, clinical and operational expertise:

• Kristina Wriston is a seasoned clinical research executive with over 30 years of experience spanning nursing, site operations, and global clinical development. She brings unmatched expertise leading phase I-IV trials and building high-performing research organizations. Kristina has driven multimillion-dollar growth, built site networks, and led hundreds of global trials across metabolic, liver, and rare diseases. She is widely respected for her strategic vision, operational rigor, and deep therapeutic knowledge.
• Adrian Di Bisceglie is a globally recognized hepatologist, with more than 40 years of leadership in liver disease research, academic medicine, and biotech innovation. Board-certified in internal medicine, gastroenterology and transplant hepatology, he has led hundreds of NIH-sponsored, industry-funded and investigator-initiated studies. A former department chair at Saint Louis University and past president of the American Association for the Study of Liver Diseases (AASLD), he is a trusted advisor to the FDA, NIH and CDC.
• Derek Vanover is a legal strategist with extensive experience supporting clients across the life sciences sector, including sponsors, clinical trial sites, and research service providers. He brings in-house CRO and pharmaceutical experience and, as a law firm founder, has represented more than 300 elite athletes. Derek is known for his solutions-focused approach to complex, high-stakes environments.

KAD Clinical Research is ready to partner with sponsors, CROs and referring physicians to accelerate the development of promising therapies and improve care for patients affected by metabolic and liver-related diseases. Launching on Global Fatty Liver Day reinforces the company’s commitment to turning scientific progress into meaningful advances for the individuals and communities most impacted by these conditions.

About KAD Clinical Research
KAD Clinical Research is an independent research site dedicated to advancing treatments for metabolic and liver-related diseases. Backed by expert leadership and a passion for better patient outcomes, the company provides comprehensive phase I-IV clinical trial execution support for sponsors and CROs while expanding patient access to breakthrough therapies. The company is focused on improving medications and treatments for conditions such as fatty liver disease, diabetes, obesity, and hyperlipidemia.

Founded to bridge scientific advancement and patient care, KAD Clinical Research is committed to increasing clinical trial access and accelerating the development of life-changing therapies. To learn more or refer a patient, contact us.